Form 4: Theravance Biopharma CEO Rick Winningham Receives 300,000 RSUs

Theravance Biopharma's CEO, Rick Winningham, was granted 300,000 Restricted Stock Units (RSUs) on April 2, 2024, with vesting conditions based on service and share price appreciation.

Summary

• On April 2, 2024, Rick Winningham, the CEO of Theravance Biopharma, received 300,000 Restricted Stock Units (RSUs).
• 150,000 of these RSUs are subject to service-based vesting conditions.
• The remaining 150,000 RSUs vest based on the achievement of share price appreciation targets and continued employment.
• Following the transaction, Winningham directly owns 1,850,573 ordinary shares.
• Winningham also indirectly owns 3,900 ordinary shares as custodian and 92,567 ordinary shares by trust.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, aligning management incentives with shareholder value. The vesting conditions based on share price appreciation are a positive sign.

Positives

• The granting of RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's share price.
• The vesting conditions based on share price appreciation targets could motivate the CEO to drive company performance and increase shareholder value.

Future Outlook

The vesting of the RSUs is contingent upon future service and the achievement of share price appreciation targets, indicating a focus on long-term performance and shareholder value.

Industry Context

Granting RSUs to executives is a common practice in the biopharmaceutical industry to align management's interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the CEO's interests with increasing shareholder value.
• Employees may be motivated by the potential for share price appreciation, which could impact their own compensation and the company's overall success.

Key Dates